<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix Closes Series D Financing - July 2011

    Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

    Biodesix Selected to Present at Multi-State Investor and Partnering Conference

    Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).

    Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

    Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

    A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.

    Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

    Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.

    Biodesix to Present at BioConference Live – Innovative Online Conference

    BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.

    VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients

    Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.

    Biodesix to Present at 2011 Biotech Showcase

    Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA

    VeriStrat® Test Predicts Outcomes in Advanced Breast Cancer Patients

    Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.

    Biodesix to Work with Concentra and Hooper Holmes to Expand Access to VeriStrat®

    The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.

    Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

    Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

    Biodesix Receives Certification from NY State

    Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.

    Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

    Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.